Concurrent Use of Capecitabine with Adjuvant Radiotherapy in the Treatment of Patients with Breast Cancer | ||||
| SECI Oncology Journal | ||||
| Article 1, Volume 6, Issue 4, December 2018, Page 56-65 PDF (968.51 K) | ||||
| DOI: 10.21608/secioj.2018.22178 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background and objectives: Patients with breast cancer have high risk of loco regional and/or distant failure. The loco regional failure rate depending mainly on the disease stage and the adjuvant treatment. Prospective randomized clinical trials have shown promising results with hypo-fractionated schedules for whole breast irradiation. Concurrent chemo radiotherapy is the standard for many solid tumors; it is promising to be investigated in breast cancer. In this study, our aim is to evaluate the toxicity, feasibility, and efficacy of concurrent capecitabine with adjuvant radiotherapy in breast cancer. Patients and methods: Data of 97 patients with stage II and III breast cancer after surgery and adjuvant chemotherapy, randomized into two groups, group A: 47 patients received concurrent chemoradiation and group B : 50 patients received radiotherapy alone. Patients were assessed for treatment toxicity and local recurrence. Results: The incidence of acute and late toxicities was comparable in both treatment groups without grade III/IV early toxicity; only a mild increase in gastrointestinal side effects was observed with capecitabine. Most of the late radiation adverse effects were grade I/II. Regarding efficacy, the concurrent capecitabine arm had better disease control locally(P value = 0.01).and better disease free survival (DFS) (P value = 0.048). Conclusion: Concurrent capecitabine with adjuvant hypofractionated radiotherapy is highly feasible, safe, and effective. | ||||
| Keywords | ||||
| breast cancer; concurrent capecitabine; Hypofractionation; adjuvant radiotherapy | ||||
|
Statistics Article View: 262 PDF Download: 286 |
||||
